Literature DB >> 23415155

Mechanisms of immune evasion in leishmaniasis.

Gaurav Gupta1, Steve Oghumu, Abhay R Satoskar.   

Abstract

Diseases caused by Leishmania present a worldwide problem, and current therapeutic approaches are unable to achieve a sterile cure. Leishmania is able to persist in host cells by evading or exploiting host immune mechanisms. A thorough understanding of these mechanisms could lead to better strategies for effective management of Leishmania infections. Current research has focused on parasite modification of host cell signaling pathways, entry into phagocytic cells, and modulation of cytokine and chemokine profiles that alter immune cell activation and trafficking to sites of infection. Immuno-therapeutic approaches that target these mechanisms of immune evasion by Leishmania offer promising areas for preclinical and clinical research.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23415155      PMCID: PMC3697132          DOI: 10.1016/B978-0-12-407679-2.00005-3

Source DB:  PubMed          Journal:  Adv Appl Microbiol        ISSN: 0065-2164            Impact factor:   5.086


  191 in total

1.  Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.

Authors:  Pramod K Kushawaha; Reema Gupta; Shyam Sundar; Amogh A Sahasrabuddhe; Anuradha Dube
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

2.  CD40-modulated dual-specificity phosphatases MAPK phosphatase (MKP)-1 and MKP-3 reciprocally regulate Leishmania major infection.

Authors:  Neetu Srivastava; Raki Sudan; Bhaskar Saha
Journal:  J Immunol       Date:  2011-04-06       Impact factor: 5.422

3.  Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites.

Authors:  N Courret; E Prina; E Mougneau; E M Saraiva; D L Sacks; N Glaichenhaus; J C Antoine
Journal:  Eur J Immunol       Date:  1999-03       Impact factor: 5.532

4.  Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation.

Authors:  J Blanchette; N Racette; R Faure; K A Siminovitch; M Olivier
Journal:  Eur J Immunol       Date:  1999-11       Impact factor: 5.532

5.  Identification of TLR inducing Th1-responsive Leishmania donovani amastigote-specific antigens.

Authors:  Ankita Srivastava; Nisha Singh; Manish Mishra; Vinod Kumar; Jalaj K Gour; Surabhi Bajpai; Sangram Singh; Haushila P Pandey; Rakesh K Singh
Journal:  Mol Cell Biochem       Date:  2011-08-20       Impact factor: 3.396

6.  Activation of phosphotyrosine phosphatase activity attenuates mitogen-activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with Leishmania donovani.

Authors:  D Nandan; R Lo; N E Reiner
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

7.  Leishmania major: secreted antigens of Leishmania major promastigotes shift the immune response of the C57BL/6 mice toward Th2 in vitro.

Authors:  Parisa-Alsadat Tabatabaee; Mohsen Abolhassani; Mehdi Mahdavi; Hossein Nahrevanian; Kayhan Azadmanesh
Journal:  Exp Parasitol       Date:  2010-07-21       Impact factor: 2.011

8.  CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.

Authors:  Yasmine Belkaid; Esther Von Stebut; Susana Mendez; Rosalia Lira; Elisabet Caler; Sylvie Bertholet; Mark C Udey; David Sacks
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

9.  Alkylacylglycerolipid domain of GPI molecules of Leishmania is responsible for inhibition of PKC-mediated c-fos expression.

Authors:  Mamta Chawla; Ram A Vishwakarma
Journal:  J Lipid Res       Date:  2003-01-01       Impact factor: 5.922

10.  Toll-like receptors in leishmania infections: guardians or promoters?

Authors:  Marilia S Faria; Flavia C G Reis; Ana Paula C A Lima
Journal:  J Parasitol Res       Date:  2012-03-15
View more
  75 in total

Review 1.  Using proteomics as a powerful tool to develop a vaccine against Mediterranean visceral leishmaniasis.

Authors:  Sajad Rashidi; Kurosh Kalantar; Gholamreza Hatam
Journal:  J Parasit Dis       Date:  2018-03-19

2.  The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Sanjay Varikuti; Greta Volpedo; Noushin Saljoughian; Omar M Hamza; Gregory Halsey; Nathan M Ryan; Bren E Sedmak; Gabriella R Seidler; Tracey L Papenfuss; Steve Oghumu; Abhay R Satoskar
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

3.  Fabrication of 3-O-sn-Phosphatidyl-L-serine Anchored PLGA Nanoparticle Bearing Amphotericin B for Macrophage Targeting.

Authors:  Pankaj K Singh; Anil K Jaiswal; Vivek K Pawar; Kavit Raval; Animesh Kumar; Himangsu K Bora; Anuradha Dube; Manish K Chourasia
Journal:  Pharm Res       Date:  2018-02-09       Impact factor: 4.200

4.  A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice.

Authors:  Bahareh Vakili; Navid Nezafat; Bijan Zare; Nasrollah Erfani; Maryam Akbari; Younes Ghasemi; Mohammad Reza Rahbar; Gholam Reza Hatam
Journal:  Med Microbiol Immunol       Date:  2019-11-06       Impact factor: 3.402

5.  Solute carrier protein family 11 member 1 (Slc11a1) activation efficiently inhibits Leishmania donovani survival in host macrophages.

Authors:  Nisha Singh; Mallikarjuna Rao Gedda; Neeraj Tiwari; Suya P Singh; Surabhi Bajpai; Rakesh K Singh
Journal:  J Parasit Dis       Date:  2016-11-12

6.  Northalrugosidine is a bisbenzyltetrahydroisoquinoline alkaloid from Thalictrum alpinum with in vivo antileishmanial activity.

Authors:  C Benjamin Naman; Gaurav Gupta; Sanjay Varikuti; Heebyung Chai; Raymond W Doskotch; Abhay R Satoskar; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2015-01-28       Impact factor: 4.050

7.  The Phenotype of Circulating Neutrophils during Visceral Leishmaniasis.

Authors:  Smriti Sharma; Shweta Srivastva; Richard E Davis; Siddharth Sankar Singh; Rajiv Kumar; Susanne Nylén; Mary E Wilson; Shyam Sundar
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

8.  Propolis reduces Leishmania amazonensis-induced inflammation in the liver of BALB/c mice.

Authors:  Suelen S da Silva; Sandra S Mizokami; Jacqueline R Fanti; Milena M Miranda; Natalia Y Kawakami; Fernanda Humel Teixeira; Eduardo J A Araújo; Carolina Panis; Maria A E Watanabe; José M Sforcin; Wander R Pavanelli; Waldiceu A Verri; Ionice Felipe; Ivete Conchon-Costa
Journal:  Parasitol Res       Date:  2015-12-28       Impact factor: 2.289

9.  Tumor suppressor p53 induces apoptosis of host lymphocytes experimentally infected by Leishmania major, by activation of Bax and caspase-3: a possible survival mechanism for the parasite.

Authors:  Mozhgan Moshrefi; Adel Spotin; Hossein Samadi Kafil; Mahmoud Mahami-Oskouei; Behzad Baradaran; Ehsan Ahmadpour; Behzad Mansoori
Journal:  Parasitol Res       Date:  2017-05-30       Impact factor: 2.289

10.  Characterization of neutrophils and macrophages from ex vivo-cultured murine bone marrow for morphologic maturation and functional responses by imaging flow cytometry.

Authors:  Margery G H Pelletier; Klaudia Szymczak; Anna M Barbeau; Gianna N Prata; Kevin S O'Fallon; Peter Gaines
Journal:  Methods       Date:  2016-09-20       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.